Introduction
Treatment of Graves' thyrotoxicosis with thionamide drugs, such as methimazole, carbimazole, and propylthiouracil, is accompanied by a decrease in thyroid autoantibody titres. '-5 These thyrostatic drugs, which are known to be accumulated in the thyroid,6 have been suggested to have an immunosuppressive effect on antibody producing lymphocytes or antigen presenting monocytes located in the thyroid.4 8 We compared the effects of methimazole combined with thyroxine and of thyroxine alone on the titres of thyroid microsomal autoantibodies in hypothyroid patients with Hashimoto's thyroiditis.
Both regimens were found to lower the antibody titres to the same extent. Department 
Subjects and methods
Twenty patients (19 women and one man), who were referred to our outpatient thyroid clinic because of hypothyroidism, participated in the study after giving their informed consent. All patients had autoimmune goitrous thyroiditis (Hashimoto's thyroiditis), the diagnosis being based on the presence of serum thyroid microsomal autoantibodies and lymphocytic thyroiditis in fine needle aspiration biopsy specimens from the thyroid. The table shows the characteristics of the 20 patients.
The study, which was approved by the ethical committee of Uppsala University, was designed as follows (figure). Ten of the patients were treated with thyroxine and methimazole for 28 weeks (group 1). Thyroxine (Levaxin; Nyegaard, Oslo, Norway) was increased gradually by 0 05 mg every second week to a final dose of 0 15 mg. Methimazole (Thacapzol; KabiVitrum, Stockholm, Sweden) was similarly increased by 10 mg every second week to a final dose of 30 mg daily. Both drugs were given by mouth three times a day. This treatment was given for another 20 weeks and then gradually withdrawn over four weeks by 0 05 mg and 10 mg, respectively, every second week. After four weeks without treatment thyroxine alone was started again as in the initial treatment period. Another 10 patients (group 2) were given the same thyroxine treatment as group 1, but methimazole was omitted.
Blood samples were drawn zero, six, 14, 22, 30, 38, 46, and 54 weeks after the start of treatment in group 1, and thyroid function was consecutively analysed by routine radioimmunoassay methods. Similarly, blood samples were drawn zero, six, 14, 22 , and 30 weeks after the start of treatment in group 2. One aliquot of serum from each sampling occasion was kept frozen at -20-C. After completion of the study all aliquots were analysed in a single assay run for the titre of thyroid microsomal autoantibodies by a commercial haemagglutination method (Thymune-M; Wellcome, Beckenham, UK).
Fine needle aspiration biopsies were performed and evaluated at the department of cytology in this hospital. Serum methimazole was determined with a gas chromatographic mass spectrometric method.' Student's t test for paired and unpaired data was used for statistical evaluation. The thyroid microsomal autoantibody titres were logarith- 
Results
The figure shows the individual and mean thyroid microsomal autoantibody titres before and after 22 weeks of treatment in the two groups of patients. The mean thyroid microsomal autoantibody titre decreased significantly in both (p < 0-01 by paired t test in both groups). In both groups the microsomal autoantibody titres decreased in eight patients and remained unchanged in two. The mean decrease was similar in the two groups (NS by t test for groups).
In three patients treatment could not, for ethical reasons, be with- All patients had a raised serum thyroid stimulating hormone concentration before treatment (table), and this returned to normal during treatment in all cases. The concentrations of thyroid stimulating hormone (geometric mean) at the end of the first period of treatment were 2 0 mU/l and 1-9 mU/l in groups 1 and 2, respectively.
In the interval without treatment hypothyroidism recurred and the mean concentration of thyroid stimulating hormone, 32 mU/l and 27 mU/l in groups 1 and 2 respectively, reached the concentration observed before the study (NS by paired t test in both groups).
Methimazole was detected in all serum samples obtained from patients in group 1, 22 weeks after the start of treatment with that drug. The mean (SEM) concentration of methimazole was 88 (9) ng/ ml. Seven of the patients in group 1 agreed to repeated fine needle aspiration thyroid biopsy in the interval without treatment, and lymphocytic thyroiditis was still present in all.
Discussion
In this study we found that hypothyroid patients with Hashimoto's thyroiditis treated with thyroxine to attain the euthyroid state showed decreased serum thyroid microsomal autoantibody titres. Addition of methimazole (30 mg daily) had Mean (SD) pretreatment data on patients with Hashimoto's thyroiditis. No significant differences were observed between the two groups Patients receiving combined thyroxine Patients receiving Variable and methimazole thyroxine alone (n= 10) (n-= 10) Age, in years 44 (17) 48 ( no further effect on the titre changes. This last finding contradicts a previous report on patients with Hashimoto's thyroiditis,9 who were treated for 12 weeks with 45 mg carbimazole (which through bioactivation, is converted to 27-5 mg methimazole."0) Carbimazole was introduced when the patients were already receiving thyroxine, and it was reported to have the effect of lowering thyroid microsomal autoantibody titres. Although the designs of these studies were not identical, no obvious explanation exists for this discrepancy. The view that antithyroid drugs are immunosuppressive in vivo is controversial." Immunosuppressive effects of methimazole in vitro on lymphocytes4 12 and monocytes7 8 17 Our data thus suggest that, in the management of patients with autoimmune disorders, immunosuppressive effects might be achieved not only by classic drugs acting directly on the immunocompetent cells but also by drugs altering the target cells within the diseased organ so that their autoimmune stimulus is reduced.
